Compare Sun Pharma with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs PROCTER & GAMBLE HEALTH - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA PROCTER & GAMBLE HEALTH SUN PHARMA/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x 21.1 53.9 39.0% View Chart
P/BV x 2.5 4.7 52.6% View Chart
Dividend Yield % 0.6 10.1 6.4%  

Financials

 SUN PHARMA   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    SUN PHARMA
Mar-19
PROCTER & GAMBLE HEALTH
Dec-18
SUN PHARMA/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs6793,549 19.1%   
Low Rs3751,301 28.8%   
Sales per share (Unadj.) Rs121.1511.4 23.7%  
Earnings per share (Unadj.) Rs13.461.3 21.8%  
Cash flow per share (Unadj.) Rs20.774.0 27.9%  
Dividends per share (Unadj.) Rs2.75440.00 0.6%  
Dividend yield (eoy) %0.518.1 2.9%  
Book value per share (Unadj.) Rs172.6927.8 18.6%  
Shares outstanding (eoy) m2,399.2616.60 14,453.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.44.7 91.8%   
Avg P/E ratio x39.439.6 99.6%  
P/CF ratio (eoy) x25.532.8 77.8%  
Price / Book Value ratio x3.12.6 116.8%  
Dividend payout %20.6717.9 2.9%   
Avg Mkt Cap Rs m1,264,65040,257 3,141.4%   
No. of employees `00017.51.1 1,543.3%   
Total wages/salary Rs m59,6711,313 4,545.7%   
Avg. sales/employee Rs Th16,608.17,486.7 221.8%   
Avg. wages/employee Rs Th3,409.61,157.6 294.5%   
Avg. net profit/employee Rs Th1,833.8897.2 204.4%   
INCOME DATA
Net Sales Rs m290,6598,490 3,423.6%  
Other income Rs m10,255244 4,204.6%   
Total revenues Rs m300,9148,734 3,445.4%   
Gross profit Rs m63,0761,482 4,257.3%  
Depreciation Rs m17,533211 8,301.4%   
Interest Rs m5,5530-   
Profit before tax Rs m50,2461,514 3,318.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-12,14466 -18,511.9%   
Tax Rs m6,009563 1,068.2%   
Profit after tax Rs m32,0931,017 3,154.4%  
Gross profit margin %21.717.5 124.4%  
Effective tax rate %12.037.1 32.2%   
Net profit margin %11.012.0 92.1%  
BALANCE SHEET DATA
Current assets Rs m310,69215,343 2,025.0%   
Current liabilities Rs m173,3961,960 8,845.8%   
Net working cap to sales %47.2157.6 30.0%  
Current ratio x1.87.8 22.9%  
Inventory Days Days9949 203.2%  
Debtors Days Days11228 392.2%  
Net fixed assets Rs m232,4771,209 19,224.1%   
Share capital Rs m2,399166 1,445.4%   
"Free" reserves Rs m411,69115,235 2,702.3%   
Net worth Rs m414,09115,401 2,688.7%   
Long term debt Rs m15,2260-   
Total assets Rs m646,93817,595 3,676.9%  
Interest coverage x10.0NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.40.5 93.1%   
Return on assets %5.85.8 100.6%  
Return on equity %7.86.6 117.3%  
Return on capital %10.210.3 99.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m66,0251,636 4,035.0%   
Fx outflow Rs m38,6104,368 883.9%   
Net fx Rs m27,415-2,732 -1,003.6%   
CASH FLOW
From Operations Rs m21,965-1,304 -1,684.7%  
From Investments Rs m-6,81312,697 -53.7%  
From Financial Activity Rs m-27,305-301 9,086.6%  
Net Cashflow Rs m-8,44211,093 -76.1%  

Share Holding

Indian Promoters % 63.7 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 5.1 18.2 28.2%  
FIIs % 23.0 1.0 2,300.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 29.1 28.5%  
Shareholders   133,026 28,591 465.3%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   GSK PHARMA  ASTRAZENECA PHARMA  BIOCON   PIRAMAL ENTERPRISES  JUBILANT LIFE SCIENCES  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Lower, India's October Exports, and Top Cues in Focus Today(Pre-Open)

India share markets ended their day marginally lower yesterday. At the closing bell yesterday, the BSE Sensex stood lower by 72 points (down 0.2%).

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (2QFY20); Net Profit Down 13.0% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 358 m (down 13.0% YoY). Sales on the other hand came in at Rs 2 bn (down 0.4% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Nov 18, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - STERLING BIOTECH COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS